BofA raised the firm’s price target on Incyte (INCY) to $104 from $90 and keeps a Buy rating on the shares after meeting with its CEO. Bill Meury highlighted his confidence in Incyte’s long-term growth potential driven by the existing commercial portfolio and maturing pipeline focusing on heme/onc and immunology and backed by a strong balance sheet, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY: